Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to calm kidney attack by antibodies

NCT ID NCT07571746

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 5 times

Summary

This study tests a drug called surovatamig in 43 adults with primary membranous nephropathy, a kidney disease caused by antibodies attacking the kidneys. The drug is given as a shot under the skin. Researchers want to see if it is safe and can reduce protein in the urine, which is a sign of kidney damage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
surovatamig
What this could lead to
If successful, this could point toward a new treatment option for people with primary membranous nephropathy, potentially reducing protein in the urine and improving kidney function.
What could go wrong
This is an early Phase 2 trial with only 43 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 43 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participant must be 18 (or the legal age of consent in the jurisdiction in which the study is taking place) to 75 years of age inclusive, at the time of signing the informed consent. 2. Diagnosis of anti-PLA2R antibody-positive pMN. 3. All participants must have received SoC therapy with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for ≥ 4 weeks, with exceptions in case of intolerance, contraindications, or low blood pressure, before the screening period. 4. Positive for anti-PLA2R. 5. Up to date with required vaccinations as per institutional guidelines (eg, influenza, pneumococcal, and severe acute respiratory syndrome coronavirus 2) prior to study entry. 6. Male and/or female assigned at birth, inclusive of all gender identities. Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. 7. Capable of giving signed informed consent Exclusion Criteria: 1. Receipt of B cell-depleting therapy including CD19- or CD20-directed monoclonal antibodies \< 9 months before screening. 2. Immunomodulatory therapy \<3 months before screening. 3. Secondary causes of membranous nephropathy 4. Diabetes mellitus with haemoglobin A1C \> 8.5% tested at screening visit. 5. Malignancies 6. History of HLH/MAS. 7 Significant CNS co-morbidity 8\. History of chronic significant respiratory disease. 9. Significant opportunistic infection in the medical history deemed relevant by the Investigator. 10\. Abnormal vital sign after 10 minutes sitting at rest. 11. Administration of corticosteroids such as prednisolone at doses exceeding 20 mg or an equivalent agent \< 2 months before screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary membranous nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic membranous glomerulonephritis membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary membranous nephropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    21 sites in 8 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    WITHDRAWN

    Los Angeles, California, 90022, United States

  • Research Site

    NOT_YET_RECRUITING

    Los Angeles, California, 90095, United States

  • Research Site

    NOT_YET_RECRUITING

    Iowa City, Iowa, 52242, United States

  • Research Site

    NOT_YET_RECRUITING

    Bethesda, Maryland, 20889, United States

  • Research Site

    NOT_YET_RECRUITING

    New York, New York, 10016, United States

  • Research Site

    RECRUITING

    Houston, Texas, 77027, United States

  • Research Site

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

  • Research Site

    NOT_YET_RECRUITING

    Ieper, 8900, Belgium

  • Research Site

    NOT_YET_RECRUITING

    Bordeaux, 33076, France

  • Research Site

    WITHDRAWN

    Créteil, 94010, France

  • Research Site

    NOT_YET_RECRUITING

    Lyon, 69009, France

  • Research Site

    NOT_YET_RECRUITING

    Nantes, 44093, France

  • Research Site

    NOT_YET_RECRUITING

    Nîmes, 30029, France

  • Research Site

    NOT_YET_RECRUITING

    Düsseldorf, 40225, Germany

  • Research Site

    NOT_YET_RECRUITING

    München, 80336, Germany

  • Research Site

    NOT_YET_RECRUITING

    Brescia, 25123, Italy

  • Research Site

    NOT_YET_RECRUITING

    Rozzano, 20089, Italy

  • Research Site

    NOT_YET_RECRUITING

    Torino, 10154, Italy

  • Research Site

    WITHDRAWN

    Verona, 37126, Italy

  • Research Site

    NOT_YET_RECRUITING

    Lodz, 92-213, Poland

  • Research Site

    NOT_YET_RECRUITING

    Barcelona, 08025, Spain

  • Research Site

    NOT_YET_RECRUITING

    Madrid, 28041, Spain

  • Research Site

    NOT_YET_RECRUITING

    London, NW3 2PF, United Kingdom

  • Research Site

    NOT_YET_RECRUITING

    Manchester, M13 9WL, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.